BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 21, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/17 cls
Akebia Therapeutics Inc. (NASDAQ:AKBA) UBS Matthew Roden New Buy 55% $26.09
Roden initiated coverage with a $28 target on the belief that Akebia's AKB-6548 has blockbuster potential to treat anemia in chronic kidney disease (CKD) patients. Roden said preclinical and clinical data support the safety of AKB-6548 vs. marketed erythropoiesis stimulating agents (ESA), which have black box warnings for increased death...

Read the full 511 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >